The broader TRIUMPH clinical trial program has enrolled more than 5,800 participants across studies examining retatrutide for obesity, overweight, obstructive sleep apnea, knee osteoarthritis, chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease
Higher dose (up to 5 mg daily): Reserved for targeted therapeutic uses under medical supervision
Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al
Diabetes 70 , 13471356 (2021)
I.MoreauC.DanelV.Mahoney-SanchezL.BouchaouiH.et al (2020)
In standard cellular models, when a cell becomes senescentmeaning it stops dividing but refuses to diethe localized foxo4 protein binds tightly to p53